Status:
UNKNOWN
Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer
Lead Sponsor:
Campus Bio-Medico University
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
There is no a clear consensus regarding the optimal treatment strategy of locally advanced pancreatic cancer. There is a potential role for neoadjuvant therapy to treat micrometastatic disease with ch...
Detailed Description
Continued optimization in multimodality therapy and an accurate patient selection remain crucial points for the appropriate treatment of patients with pancreatic cancer. In all patients an accurate pr...
Eligibility Criteria
Inclusion
- proven cytological or histological diagnosis of pancreatic ductal adenocarcinoma;
- borderline resectable or unresectable pancreatic tumours;
- no previous radiochemotherapy to abdomen;
- 0-I Eastern Cooperative Oncology Group (ECOG) performance status;
- adequate cardiac, liver and kidney function and a good bone marrow reserve.
Exclusion
- resectable and metastatic disease;
- previous or concomitant malignant disease;
- one or more of the following clinical conditions: infection, pregnancy or breast-feeding, liver failure, kidney failure, Pa O2 \< 65 mmHg, Pa carbon dioxide (CO2) \> 40 mmHg, mental disability.
Key Trial Info
Start Date :
July 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05399394
Start Date
July 1 2016
End Date
June 1 2022
Last Update
June 1 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.